biosimilars

News

Sandoz weighs into European rituximab biosimilar market

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon.

News

Sandoz files Humira and Remicade biosimilars in EU

European regulators to review Sandoz’s Humira and Remicade biosimilars.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

QuintilesIMS Webinar 2017 Biologics_16x9_8June2017

Disruption and maturity: the future directions for biologics

Is the UK’s NHS saving enough from the new wave of biosimilars?

News

Celltrion's rituximab biosimilar could have four names in EU

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.

News

J&J looks to Actelion to boost sales after poor Q1

Johnson & Johnson is hoping its new acquisition Actelion will help stave off the effects of a price squeeze in the US, and a cheaper biosimilar of its bestseller, Remicade.

News

Roche keeps Rituxan evergreen with Breakthrough designation,...

Roche is finding new ways to keep its oncology and rheumatoid arthritis blockbuster Ri

Sandoz weighs into European rituximab biosimilar market

Sandoz files Humira and Remicade biosimilars in EU

Disruption and maturity: the future directions for biologics

Celltrion's rituximab biosimilar could have four names in EU

J&J looks to Actelion to boost sales after poor Q1

Roche keeps Rituxan evergreen with Breakthrough designation,...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

biosimilars

Editor's Picks